Abstract 603
Background
Observational studies show that Alzheimer’s disease (AD) and lung cancer is negatively associated in both directions. However, whether there is a causal relationship between AD and lung cancer remains uncertain. Mendelian Randomization (MR) is a novel approach for the assessment of causality, using genome-wide significant single-nucleotide polymorphisms (SNP) as instrument variables (IV) to eliminate the bias caused by confounders. In this study, we utilized a bi-directional two-sample MR analysis to estimate the potential causality between AD and lung cancer.
Methods
The genome-wide association study (GWAS) summary data of AD and lung cancer were derived from the International Genomics of Alzheimer’s Project (IGAP,17,008 AD cases and 37,154 controls) and the International Lung Cancer Consortium (ILCCO, 11,348 lung cancer cases and 15,861 controls), respectively. We performed a bi-directional two-sample MR analysis to determine the causal relationship between AD and lung cancer. To be specific, Inverse-Variance Weighted (IVW), MR-Egger and Weighted Median methods were utilized for deriving causal estimates. Single SNP analysis and leave-one-out analysis were also conducted to identify if a single SNP is driving the association. We also performed the MR-Egger regression and MR-PRESSO analysis for the evaluation of horizontal pleiotropy.
Results
There was no causal relationship between AD and lung cancer in bi-directional MR. The results of Single SNP analysis and leave-one-out analysis indicated that no single SNP was driving the association. No directional horizontal pleiotropy was detected in the MR-Egger regression analysis. The MR-PRESSO analysis did not detect horizontal pleiotropy. There was no evidence for violations of MR assumptions in the sensitivity analysis.Table:
1847P Mendelian randomization estimates of the causality
Exposure | Outcome | Inverse Variance Weighted | MR Egger | Weighted Median | |||
---|---|---|---|---|---|---|---|
OR (95%CI) | P-value | OR (95%CI) | P-value | OR (95%CI) | P-value | ||
Alzheimer’s Disease | Lung Cancer | 1.040 (0.965-1.121) | 0.299 | 1.033 (0.890-1.199) | 0.676 | 0.999 (0.902-1.106) | 0.980 |
Lung Cancer | Alzheimer’s Disease | 0.919 (0.794-1.062) | 0.253 | 1.223 (0.597-2.504) | 0.637 | 0.920 (0.836-1.013) | 0.091 |
Conclusions
We found no causality between AD and lung cancer through the two-sample MR analysis. However, further study is warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Key R&D Program of China (Grant No. 2016YFC0905500, 2016YFC0905503).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2045 - The analysis of treatment sequences and clinical outcomes of thymic carcinoma
Presenter: Arakaki Motoko
Session: Poster Display session 1
Resources:
Abstract
4785 - Transcriptomic Difference of Thymoma and Thymic Carcinoma
Presenter: Naixin Liang
Session: Poster Display session 1
Resources:
Abstract
2864 - A Phase II Trial of Preoperative Chemoradiotherapy and Pembrolizumab for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)
Presenter: Seoyoung Lee
Session: Poster Display session 1
Resources:
Abstract
5015 - The study of tumor associated exosomes in crosstalk between esophageal carcinoma and lymphatic endothelial cells
Presenter: Weimin Mao
Session: Poster Display session 1
Resources:
Abstract
1339 - Up-regulation of IBSP expression predicts poor prognosis of Esophageal Squamous Cell Carcinoma patients
Presenter: Mingyue Wang
Session: Poster Display session 1
Resources:
Abstract
4083 - PD-L1 expression in primary tumour vs metastatic samples in the Phase 3 MYSTIC study in first-line metastatic (m) NSCLC
Presenter: Niels Reinmuth
Session: Poster Display session 1
Resources:
Abstract
5113 - Assessing the impact of subsequent checkpoint inhibitor (CPI) treatment on overall survival: post hoc analyses from the phase 3 JAVELIN Lung 200 study of avelumab vs docetaxel in platinum-treated locally advanced/metastatic non-small cell lung cancer (NSCLC)
Presenter: Fabrice Barlesi
Session: Poster Display session 1
Resources:
Abstract
4256 - Long-term avelumab treatment in patients with advanced non-small cell lung cancer (NSCLC): post hoc analyses from JAVELIN Solid Tumor
Presenter: Borys Hrinczenko
Session: Poster Display session 1
Resources:
Abstract
4305 - Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: Updated survival and subgroup analysis from the real-world EVIDENS study
Presenter: Fabrice Barlesi
Session: Poster Display session 1
Resources:
Abstract
5128 - IO-Synthesise NSCLC: A pooled analysis of real-world survival outcomes for non-small cell lung cancer patients treated with nivolumab in France and Germany
Presenter: Adrien Dixmier
Session: Poster Display session 1
Resources:
Abstract